Focussing on  early stage oral cancer treatments using a conjugated HDACi-LightOx photosensitiser. This new class of drug can be targeted at certain cell types and activated using a specific wavelength of light making them toxic to the cell and causing cell death.

By targeting the therapies to oral cancers LightOx are able to treat patients with the early stage cancer, and enable pre-cancerous treatments before surgical intervention. LightOx will then develop new drug compounds to market for other clinical areas, where light activated treatment is possible, including bladder.

Processing. Please wait.